Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-4615-2443-4_5 | DOI Listing |
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFBest Pract Res Clin Haematol
December 2024
Institute for Experimental Cellular Therapy, University Hospital Essen, Germany. Electronic address:
J Immunol
February 2025
Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.
View Article and Find Full Text PDFCancer Immunol Immunother
March 2025
Medical Genetics Institute, Ho Chi Minh City, Vietnam.
Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research, we evaluated the safety and therapeutic efficacy of synthetic long peptide and mRNA-based vaccines, both designed to target identical neoantigens across different Lewis Lung Carcinoma (LLC) tumor burdens. We employed the LLC syngeneic mouse model, a widely used preclinical model for aggressive and immunosuppressive tumors.
View Article and Find Full Text PDFSovrem Tekhnologii Med
March 2025
MD, PhD, Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
Unlabelled: One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques. was to evaluate the impact efficacy of "enhanced" NK cells on early metabolic rearrangements and the viability of glioblastoma cells in a patient using a tumor spheroid model.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!